SEC reporting owner

Flagship Ventures Fund IV General Partner LLC SEC insider disclosures

Explore Flagship Ventures Fund IV General Partner LLC's reporting-owner identity, issuer relationships, purchases, sales and SEC filing receipts.

As of 2026-10-07T00:29:11.873Z

Reporting owner CIK
0001508051
Issuers
11
Coverage
verified

Issuer relationships

A reporting-owner CIK identifies the filer across issuer relationships and name aliases. A filer may be an individual or an organization; the filing role is the relevant evidence.

Eleven Biotherapeutics, Inc.0001485003EBIONoNo
T2 Biosystems, Inc.0001492674TTOONoNo
Seres Therapeutics, Inc.0001609809MCRBNoNo
Editas Medicine, Inc.0001650664EDITNoNo
Syros Pharmaceuticals, Inc.0001556263SYRSNoNo
Evelo Biosciences, Inc.0001694665EVLONoNo
Rubius Therapeutics, Inc.0001709401RUBYNoYes
Moderna, Inc.0001682852MRNANoYes
Kaleido Biosciences, Inc.0001751299KLDONoYes
TransMedics Group, Inc.0001756262TMDXNoNo
Axcella Health Inc.0001633070AXLANoNo

Recent SEC transactions

Code P identifies a purchase, S a sale and A an award. Awards and open-market purchases describe different events. Use the public availability date when deciding when a researcher could have known about the transaction.

No records are available for this view.

Up to 50 transactions from the recent two-year owner window.

Source evidence and strategy eligibility

The transactions below come from filings; a historical tracker separately simulates following eligible events. Joint filers can report the same transaction, and an owner can have filings at multiple companies. Public availability, amendment lineage and verified coverage determine which events a historical tracker may use.

The current directory marks this owner's filing coverage verified.